U.S. Markets closed

Cempra, Inc. (CEMP)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
4.3500+0.2500 (+6.0976%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close4.1000
Bid4.0000 x 600
Ask13.0000 x 100
Day's Range4.1000 - 4.3500
52 Week Range2.5500 - 26.9500
Avg. Volume767,595
Market Cap228.39M
PE Ratio (TTM)-2.01
EPS (TTM)-2.17
Earnings DateAug 9, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.21
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Cempra to Report Second Quarter 2017 Financial Results

    CHAPEL HILL, N.C., July 20, 2017-- Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical ...

  • Capital Cube22 days ago

    ETFs with exposure to Cempra, Inc. : June 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cempra, Inc. Here are 5 ETFs with the largest exposure to CEMP-US. Comparing the performance and risk of Cempra, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • American City Business Journals23 days ago

    In case of sale, Cempra execs primed for golden parachutes

    Chapel Hill-based Cempra (CEMP) – which has struggled to regain footing after the U.S. Food and Drug Administration did not approved its pneumonia drug solithromycin in December of last year – has disclosed in an SEC filing that, should a sale of the company ensue, its acting CEO and other C-suite executives are primed for golden parachutes. According to the filing, the company has entered into a change in control severance agreement with acting CEO Dr. David Zaccardelli and into an amended change in control severance agreement with its Chief Financial Officer Mark Hahn, Chief Medical Officer Dr. David Oldach, and Executive Vice President of Investor Relations and Corporate Communications John Bluth. The agreements come at a time when the company is reviewing strategic options , having retained Morgan Stanley as a financial advisor to assist in that effort earlier this year.